Clinical Trial Update: Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations [Phase 1]

View source ↗

Summary

Phase 1 study of oral LY3410738 in patients with IDH1/IDH2-mutant hematologic malignancies is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes
• Myelomonocytic Leukemia
• Myeloproliferative Neoplasms

Drugs mentioned

• LY3410738 (LY3410738)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) | Phase 1 | Status: ACTIVE_NOT_RECRUITING